Differences in adjuvant chemotherapy and oncological outcomes according to margin status in patients with stage III colon cancer

References

• Birbeck KF, Macklin CP, Tiffin NJ, et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg. 2002;235(4):449–457.
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol. 2002;26(3):350–357.
   PubMed Web of Science ®Google Scholar
• Khan MA, Hakeem AR, Scott N, et al. Significance of R1 resection margin in colon cancer resections in the modern era. Colorectal Dis. 2015;17(11):943–953.
   PubMed Web of Science ®Google Scholar
• Scott N, Jamali A, Verbeke C, et al. Retroperitoneal margin involvement by adenocarcinoma of the caecum and ascending colon: what does it mean? Colorectal Dis. 2008;10(3):289–293.
   PubMed Web of Science ®Google Scholar
• Smith HG, Chiranth D, Mortensen CE, et al. The significance of subdivisions of microscopically positive (R1) margins in colorectal cancer: a retrospective study of a national cancer registry. Colorectal Dis. 2022;24(2):197–209.
   PubMed Web of Science ®Google Scholar
• Smith HG, Skovgaards DM, Chiranth D, et al. The impact of subdivisions of microscopically positive (R1) margins on patterns of relapse in stage III colorectal cancer - A retrospective cohort study. Colorectal Dis. 2022;24(7):828–837.
   PubMed Web of Science ®Google Scholar
• Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378(13):1177–1188.
   PubMed Web of Science ®Google Scholar
• Smith HG, Chiranth DJ, Schlesinger NH. Do differences in surgical quality account for the higher rate of R1 margins to lymph node metastases in right- versus left-sided stage III colon cancer: a retrospective cohort study. Colorectal Dis. 2023;25(4):679–687 .
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–349.
   PubMed Web of Science ®Google Scholar
• Klein MF, Gogenur I, Ingeholm P, et al. Validation of the Danish colorectal cancer group (dccg.dk) database - on behalf of the Danish colorectal cancer group. Colorectal Dis. 2020;22(12):2057–2067.
   PubMed Web of Science ®Google Scholar
• Argiles G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291–1305.
   PubMed Web of Science ®Google Scholar
• Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139.
   PubMed Web of Science ®Google Scholar
• Niedzwiecki D, Frankel WL, Venook AP, et al. Association between results of a gene expression signature assay and recurrence-free interval in patients with stage II colon cancer in cancer and leukemia group B 9581 (alliance). J Clin Oncol. 2016;34(25):3047–3053.
   PubMed Web of Science ®Google Scholar
• Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29(35):4611–4619.
   PubMed Web of Science ®Google Scholar
• Henriksen TV, Tarazona N, Frydendahl A, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res. 2022;28(3):507–517.
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261–2272.
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116.
   PubMed Web of Science ®Google Scholar
• Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–1471.
   PubMed Web of Science ®Google Scholar
• Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–2204.
   PubMed Web of Science ®Google Scholar
• Mukund K, Syulyukina N, Ramamoorthy S, et al. Right and left-sided colon cancers–specificity of molecular mechanisms in tumorigenesis and progression. BMC Cancer. 2020;20(1):317.
   PubMed Web of Science ®Google Scholar
• Foxtrot Collaborative G. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13(11):1152–1160.
   PubMed Web of Science ®Google Scholar
• Nerad E, Lahaye MJ, Maas M, et al. Diagnostic accuracy of CT for local staging of colon cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2016;207(5):984–995.
   PubMed Web of Science ®Google Scholar
• Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566–576.
   PubMed Web of Science ®Google Scholar
• McCall JL, Black RB, Rich CA, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum. 1994;37(9):875–881.
   PubMed Web of Science ®Google Scholar
• Tsai HL, Chu KS, Huang YH, et al. Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol. 2009;100(8):736–743.
   PubMed Web of Science ®Google Scholar
• Brouwer NPM, Nagtegaal ID. Tumor deposits improve staging in colon cancer: what are the next steps? Ann Oncol. 2021;32(10):1209–1211.
   PubMed Web of Science ®Google Scholar